Summary of Good News for Listed Companies on the Evening of March 1(List of Names)

Several listed companies in the Shanghai and Shenzhen markets released important announcements on the evening of March 1. Here is a summary of the positive news:

Hua An Securities: Anhui Guokong Group plans to increase holdings by no more than 2%

Hua An Securities announced that its controlling shareholder, Anhui Provincial State-owned Capital Operation Holding Group Co., Ltd., holds 1.139 billion shares, accounting for 23.93%; together with concerted parties, they hold 1.639 billion shares, accounting for 34.44%. From February 26 to 27, 2026, through centralized bidding, they purchased 41,010 Hua An convertible bonds and converted all, receiving 19,031 shares, representing 0.0004%. Anhui Guokong Group plans to increase its stake via convertible bond purchases and conversions from March 2 to March 6, 2026, with a total investment of 150 million to 300 million yuan, increasing holdings by no more than 2%. The funds will come from its own resources, and it commits not to reduce holdings within six months after the increase is completed.

Aidi Pharmaceutical: One of the actual controllers, Chairman Fu Heliang, plans to increase holdings by 10 million to 15 million yuan

Aidi Pharmaceutical announced that Fu Heliang, one of its actual controllers and chairman, plans to increase his holdings within six months starting March 2, 2026, through the Shanghai Stock Exchange trading system via centralized bidding or block trades. The increase will be no less than 10 million yuan and no more than 15 million yuan, funded by his own or raised funds.

Kanghong Pharmaceutical: Eight products selected in national centralized procurement, procurement cycle until the end of 2028

Kanghong Pharmaceutical announced that eight products—citrus mosapride tablets, risperidone tablets, venlafaxine hydrochloride sustained-release tablets, aripiprazole orally disintegrating tablets, oxalate escitalopram tablets, pramipexole hydrochloride sustained-release tablets, quetiapine fumarate tablets, and sodium hyaluronate eye drops—were selected in the continuation of national organized procurement. The first two products, quetiapine fumarate tablets and sodium hyaluronate eye drops, are participating in the renewal process for the first time. The results are scheduled to be implemented in March 2026, with the procurement cycle ending December 31, 2028.

Zhongyuan Xiehe: Subsidiary received medical device registration certificate, first domestically approved tumor companion diagnostic kit using flight time mass spectrometry

Zhongyuan Xiehe announced that its controlling subsidiary recently received a Class III medical device registration certificate from the National Medical Products Administration for a gene mutation detection kit (EGFR/KRAS/BRAF/ERBB2/PIK3CA) using flight time mass spectrometry. This is the first domestically approved tumor companion diagnostic kit based on flight time mass spectrometry, used for detecting gene mutations in non-small cell lung cancer and colorectal cancer patients, with related drugs included in the national medical insurance catalog. The approval enriches the company’s tumor companion diagnostic product line, but its future impact on performance is unpredictable.

YiduoLi: Subsidiary’s phytase product approved for registration in the EU

YiduoLi announced that its wholly owned subsidiary, Victory Enzymes GmbH in Germany, recently received approval from the European Commission for its phytase product, which can be used as a feed additive for pigs, poultry, and some birds in the EU market. The authorization is valid until March 17, 2036. This approval expands the company’s product portfolio in the EU, enhances global deployment, and improves market competitiveness and brand influence. However, future sales are uncertain, and investors should be cautious of risks.

Henghua Technology: Pre-bid winning of a 630 million yuan wind power EPC project

Henghua Technology announced that it recently participated in the bidding for the “Longhua County 100MW Wind Power Project Design, Procurement, and Construction (EPC)” and was listed as the first candidate for winning, with a bid price of 630 million yuan. The project plans to install 100MW of wind power capacity, with a construction period of 296 calendar days. If awarded and successfully implemented, it is expected to positively impact the company’s future performance.

Tiancheng Automation: Subsidiary received client project designation notice

Tiancheng Automation announced that its wholly owned subsidiary, Wuhan Tiancheng Automation Automotive Seat Co., Ltd., recently received a project designation notice from a globally renowned joint venture automaker (name confidential under a nondisclosure agreement). Wuhan Tiancheng has been designated as a supplier for a passenger car seat assembly project. The project is expected to start mass production in December 2026, with a lifecycle of five years and an estimated supporting volume of 250,000 vehicles during the project period. The project is expected to start mass production in December 2026 and will not significantly impact this year’s performance but is expected to have a positive effect on future performance. The specific impact amount and timing depend on order details.

Xinmai Medical: Hector thoracic multi-branch stent receives FDA Breakthrough Device designation

Xinmai Medical announced that its innovative Hector / Tongtianji thoracic aorta multi-branch covered stent system received FDA Breakthrough Device Designation on February 27, 2026. The product is used for minimally invasive treatment of thoracic aortic lesions involving the three branches of the aortic arch.

(Source: Eastmoney Research Center)